Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D and Phosphate: Hormone Feedback, Bone and Energy: Study Summary

Previous related pageVitamin D and Phosphate: Hormone Feedback, Bone and Energy: Full Evidence ReviewNext related pageVitamin D and Phosphate: Hormone Feedback, Bone and Energy: Full Evidence Review
Study at a glance

What was studied?

This summary covers vitamin D, phosphate regulation, addition of mineral to bone, and muscle energy. Researchers studied people, rats and mice. The human bone study involved a rare condition in which the kidneys lose too much phosphate.

What was found?

A D2 trial increased a phosphate-regulating hormone, while a separate D3 trial did not clearly change its different hormone measurement. In mice, steady blood phosphate could accompany changed absorption and loss in urine. High blood phosphate could occur with poor addition of mineral to bone. Separately, mice with low phosphate had resting ATP amounts similar to controls but poorer muscle recovery. ATP is a molecule used in energy transfer.

What does it mean?

Phosphate regulation involves several organs and hormones. Blood results, bone samples and muscle measurements answer different questions. The vitamin D form and study model must remain clear. The human D2 and D3 studies were not a direct comparison.

What are the main limits?

Animal findings do not establish treatment effects in people. The small disease-specific bone study had no control group. The muscle experiments did not test D3 supplementation. No personal supplement dose or blood target follows from this evidence.

Read the full article below ↓

Vitamin D helps regulate phosphate through a system involving the intestine, kidneys, bone and hormones. The studies reviewed here explain parts of that system and examine what happens when phosphate handling changes. They include experiments in animals, human supplement trials and a small study of adults with a phosphate-wasting disease. Their findings do not establish one effect of vitamin D for every bone or energy-related outcome. For the detailed appraisal, read Vitamin D and Phosphate: Hormone Feedback, Bone and Energy: Full Evidence Review.

What keeps phosphate in balance?

Phosphate contributes to bone mineral and to molecules involved in cellular energy. The body must absorb it, retain an appropriate amount and remove what it does not need. A blood phosphate measurement gives useful information, but does not directly measure all those movements.

Vitamin D and Kidneys explains the organ that adjusts urinary phosphate loss. The hormone FGF23 and parathyroid hormone help coordinate that process with vitamin D metabolism. FGF23 means fibroblast growth factor 23. It is a hormone involved in communication between bone and other organs.

The form of vitamin D matters. Vitamin D2 and vitamin D3 are starting forms that the body can convert into other forms. Calcitriol is an activated hormone. Giving calcitriol to an animal is different from giving a supplement that must be converted before supplying active hormone. Removing a hormone or receptor throughout a mouse is another distinct experiment.

What did the regulation studies find?

Mice without FGF23 retained more phosphate through their kidneys and developed high phosphate and calcitriol. Several substances changed together, and the animals had severe developmental problems. The results show the importance of coordinated regulation; they do not predict the effect of ordinary D3 supplementation in people.

The human trial results differed. A vitamin D2 trial found increased FGF23 using a test that measures the whole hormone. A separate D3 trial used a different FGF23 test and did not find a clear overall increase. The studies differed in participants, schedule and measurement method. They were not a direct D2-versus-D3 comparison. Phosphate loss rose within the D2 group, but the comparison with placebo did not clearly show a difference between groups.

In ten healthy young men, more available phosphate raised blood phosphate and phosphate loss in urine; parathyroid hormone and calcitriol showed no clear change.

Other experiments showed why the organ and condition matter. Normal rat parathyroid glands responded to FGF23, while glands from rats with severe kidney disease resisted that effect. In mice, calcitriol increased active intestinal absorption through a specific transporter, a protein that moves phosphate into cells. Passive absorption between cells did not increase in the same way. Blood phosphate could remain stable while absorption and urinary loss changed.

What happened to bone and muscle?

Vitamin D and Bone concerns mineral deposition and tissue structure. The phosphate studies showed that high blood phosphate did not always accompany healthy bone. In another mouse experiment, removing vitamin D activation reduced abnormal mineral deposits outside bone but worsened skeletal mineralisation. A favourable change in one place did not mean that every tissue improved.

In growing mice, low phosphate disrupted normal removal of enlarged cartilage cells near the ends of bones; this finding does not establish effects in adult human bone.

The human bone study involved adults with X-linked hypophosphataemia, a rare condition in which the kidneys lose too much phosphate. Fourteen enrolled, and ten could be assessed for the main bone-sample measurement. Treatment directed at FGF23 improved several measures of bone material that had not yet become mineralised. The study had no control group and improvement was incomplete. Some missing results had to be estimated, and the estimated time for new bone material to become mineralised remained uncertain. It was not a trial of vitamin D3.

Two mouse studies examined muscle metabolism under different phosphate conditions. With phosphate deficiency, resting ATP could be similar to control values while recovery after contractions was worse. ATP is a molecule used in energy transfer. With excessive phosphate, another study found less measured use of fat for energy and shorter exercise duration. Neither experiment tested whether D3 improved energy in people.

What do these findings mean?

Vitamin D participates in a system in which several organs and hormones influence phosphate handling. It does not control every phosphate outcome by itself. Vitamin D and Calcium Physiology gives the related calcium-and-hormone setting. Blood concentrations, transport measurements, bone samples and muscle recovery describe different aspects of the system.

The evidence does not identify a personal supplement dose, phosphate intake or blood target. Animal interventions, small disease-specific studies and human precursor trials each have limits. Their main contribution is to explain why phosphate handling and its consequences must be assessed together, while keeping the actual intervention and measured outcome clear.

Primary sources and publication details

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. Shimada T and colleagues. Journal of Clinical Investigation. 2004;113:561 to 568. DOI: 10.1172/jci19081. PMID: 14966565.

Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Burnett-Bowie SA and colleagues. Clinical Journal of the American Society of Nephrology. 2012;7:624 to 631. DOI: 10.2215/cjn.10030911. PMID: 22300739.

The parathyroid is a target organ for FGF23 in rats. Ben-Dov IZ and colleagues. Journal of Clinical Investigation. 2007;117:4003 to 4008. DOI: 10.1172/jci32409. PMID: 17992255.

Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels. Gerber JS and colleagues. Pflügers Archiv. 2025;477:495 to 508. DOI: 10.1007/s00424-024-03046-4. PMID: 39601886.

Effects of vitamin D supplementation on FGF23: a randomized-controlled trial. Trummer C and colleagues. European Journal of Nutrition. 2019;58:697 to 703. DOI: 10.1007/s00394-018-1672-7. PMID: 29602956.

FGF23 fails to inhibit uremic parathyroid glands. Canalejo R and colleagues. Journal of the American Society of Nephrology. 2010;21:1125 to 1135. DOI: 10.1681/asn.2009040427. PMID: 20431039.

1,25(OH)2 vitamin D3 stimulates active phosphate transport but not paracellular phosphate absorption in mouse intestine. Hernando N and colleagues. Journal of Physiology. 2021;599:1131 to 1150. Accepted manuscript inspected. DOI: 10.1113/jp280345. PMID: 33200827.

Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Sabbagh Y, Carpenter TO and Demay MB. Proceedings of the National Academy of Sciences USA. 2005;102:9637 to 9642. DOI: 10.1073/pnas.0502249102. PMID: 15976027.

Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Sitara D and colleagues. American Journal of Pathology. 2006;169:2161 to 2170. DOI: 10.2353/ajpath.2006.060329. PMID: 17148678.

Defective adenosine triphosphate synthesis. An explanation for skeletal muscle dysfunction in phosphate-deficient mice. Hettleman BD and colleagues. Journal of Clinical Investigation. 1983;72:582 to 589. DOI: 10.1172/jci111006. PMID: 6874957.

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial. Insogna KL and colleagues. Journal of Bone and Mineral Research. 2019;34:2183 to 2191. DOI: 10.1002/jbmr.3843. PMID: 31369697.

High-Phosphate Diet Induces Exercise Intolerance and Impairs Fatty Acid Metabolism in Mice. Peri-Okonny P and colleagues. Circulation. 2019;139:1422 to 1434. Early-online principal copy inspected. DOI: 10.1161/circulationaha.118.037550. PMID: 30612451.

Related reading

Original sources